147 related articles for article (PubMed ID: 2499263)
1. [The usefulness and limitation of sugar antigen in ovarian cancers--with special reference to a new tumor marker, CA54/61].
Nozawa S
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1147-51. PubMed ID: 2499263
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated mucin-type glycoprotein (CA54/61) defined by two monoclonal antibodies (MA54 and MA61) in ovarian cancers.
Nozawa S; Yajima M; Kojima K; Iizuka R; Mochizuki H; Sugawara T; Iwamori M; Nagai Y
Cancer Res; 1989 Jan; 49(2):493-8. PubMed ID: 2910468
[TBL] [Abstract][Full Text] [Related]
3. [The evaluation of CA54/61 in the diagnosis of ovarian cancer--with special reference to the cooperative results of 5 institutes].
Nozawa S; Yajima M; Udagawa Y; Kiguchi K; Iizuka R; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1823-9. PubMed ID: 2687409
[TBL] [Abstract][Full Text] [Related]
4. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies MA54 and MA61 as potential reagents in the prognosis of patients with ovarian cancer.
Kobayashi H; Ohi H; Sugimura M; Shinohara H; Terao T
Gynecol Oncol; 1993 Apr; 49(1):80-5. PubMed ID: 8482565
[TBL] [Abstract][Full Text] [Related]
6. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
8. Serum placental alkaline phosphatase (PLAP) in gynecologic malignancies--with special reference to the combination of PLAP and CA54/61 assay.
Nozawa S; Udagawa Y; Ohkura H; Negishi Y; Akiya K; Inaba N; Takamizawa H; Kimura E; Terashima Y
Clin Chim Acta; 1990 Jan; 186(2):275-84. PubMed ID: 2178810
[TBL] [Abstract][Full Text] [Related]
9. [On the clinical usefulness of a few sugar antigens and a galactosyl-transferase].
Nozawa S; Izumi S; Sakayori M; Narisawa S; Kojima K; Iizuka R; Iwamori M; Nagai Y
Hum Cell; 1988 Mar; 1(1):37-45. PubMed ID: 3155288
[TBL] [Abstract][Full Text] [Related]
10. [Galactosyltransferase isozyme II (GT-II) as a new tumor marker for ovarian cancers--especially for clear cell carcinoma].
Nozawa S; Kiguchi K; Yajima M; Udagawa Y; Sakuma T; Iizuka R; Narisawa S; Sakayori M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1341-7. PubMed ID: 2511259
[TBL] [Abstract][Full Text] [Related]
11. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
13. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
14. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
16. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
18. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
Rao GS; Hanjani P
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
[TBL] [Abstract][Full Text] [Related]
19. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
Ito K; Udagawa Y; Nozawa S
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
